Marc Hafner

[Marc Hafner @marchafner]

https://t.co/z73ZmKKobW

[Marc Hafner @marchafner]

I am proud to share our most recent paper on the landscape of alterations in HR+ breast cancer prevention- and post-1L. We addressed challenges inherent to working with RWD, and validated our findings using clinical trial data. Great collaborations across Genentech/Roche.

[Marc Hafner @marchafner]

Final manuscript published in cell chem biol: https://t.co/ddG8WoNUT8. https://t.co/ltUuE08rat

[Marc Hafner @marchafner]

Thanks for the positive comments

[Albert A. Antolin (he/him) @antolin_aa]

Impressive multiomics analysis by the Sorger Lab uncovers the potential clinical relevance of the differential kinase polypharmacology between the "CDK4/6 drugs" abemaciclib, palbociclib and ribociclib @CellChemBiol https://t.co/ZT3L198wWk

[Marc Hafner @marchafner]

HMS news about our CDK4/6 paper: Head to Head | Harvard Medical School https://t.co/aiLiriRiqp

[Marc Hafner @marchafner]

@genomematt Final version is now published in Cell Chem Biol: https://t.co/uGcwnA7EgC

[Marc Hafner @marchafner]

@gerlach_d Final version is now published in Cell Chem Biol: https://t.co/uGcwnzQ2S2

[Marc Hafner @marchafner]

@MJ_Humphries Final version is now published in Cell Chem Biol: https://t.co/uGcwnzQ2S2

[Marc Hafner @marchafner]

@ProtifiLlc Final version is now published in Cell Chem Biol: https://t.co/uGcwnzQ2S2

[Marc Hafner @marchafner]

@ProtifiLlc Final version is now published in Cell Chem Biol: https://t.co/uGcwnzQ2S2

[Marc Hafner @marchafner]

My latest postdoc article on CDK46 inhibitors in breast cancer is out: https://t.co/ddG8WoNUT8
Thanks to Caitlin Mills, @rskartik and others for the great collaboration
#CDK46 #breastcancer #CancerResearch #sysbio

[Marc Hafner @marchafner]

Thanks for your interest in our work!

[Daniel Gerlach @gerlach_d]

Macros Malumbres keeping up with the literature citing a paper published yesterday on BioRxiv - zoom in on the lower right #enasymp

[Marc Hafner @marchafner]

Our work being discussed at EORTC/AACR meeting. Latest version here: https://t.co/xggbjMFyJY
Next presentation at San Antonio Breast Cancer Symposium

[Marc Hafner @marchafner]

Latest version of our paper: Multi-omics profiling establishes the polypharmacology of FDA Approved CDK4/6 inhibitors and its impact on… https://t.co/yseZJR0rJU

[Marc Hafner @marchafner]

Therapeutically advantageous secondary targets of abemaciclib identified by multi-omics profiling of CDK4/6 inhibitors https://t.co/gFEF07PdAC #breastcancer #cdk46 #palbociclib #abemaciclib #ribociclib @rskartik

[Marc Hafner @marchafner]

Therapeutically advantageous secondary targets of abemaciclib identified by multi-omics profiling of CDK4/6 inhibitors https://t.co/GxPDuoUvRK

[Marc Hafner @marchafner]

My latest paper is out: Alternative drug sensitivity metrics improve preclinical cancer pharmacogenomics https://t.co/VZKIWemMnC

[Marc Hafner @marchafner]

Tonia came third at the ITT, one minute faster than just year! @harvardcycling https://t.co/mYc2Wpu3KP

[One2Go_Results @One2Go_Results]

2016 @USACcollegiate Individual Time Trial National Championships Summary #collnats

[Marc Hafner @marchafner]

@harvardcycling https://t.co/gs7UTqFgTC

[Cal Cycling @CalCycling]

And there off at the DI women @USACcollegiate nationals RR #Collnats #gobears

[NorthStarGrandPrix @NSBikeFest]

Final lap of the Women's #CollNats Road Race for the D1 field!
@USACcollegiate @usacycling https://t.co/GRTBYFycSz